Corxel, an obesity drugmaker, to go public via SPAC deal
Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight loss-focused company to join the public
DO
By Daniel Okafor · Regulatory Correspondent
Oct 26 15:17 ETSource: BioPharma Dive
From the source
Read at biopharmadive.comCorxel, an obesity drugmaker, to go public via SPAC deal
Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight loss-focused company to join the public markets.
